China Merchants Health led a CNY520m (~USD76m) Series B for Porton Advanced Solutions, a China-based contract development and manufacturing organization (CDMO) focused on gene and cell therapy services, with participation from China Merchants Securities, China Merchants Capital, Fosun Health Capital and SDIC Taikang Trust, and follow-on from CMG-SDIC Capital, HM Capital, Ruilian Investment, Momentum Venture and its parent company Porton Pharma Solutions. Read more here and here